Ads
related to: cyclosporine 0.05 eye drops side effects in women 20 mg capsule para que sirve
Search results
Results From The WOW.Com Content Network
Ciclosporin, also spelled cyclosporine and cyclosporin, is a calcineurin inhibitor, used as an immunosuppressant medication.It is taken orally or intravenously for rheumatoid arthritis, psoriasis, Crohn's disease, nephrotic syndrome, eczema, and in organ transplants to prevent rejection.
Side effects include burning sensation (common), [4] redness, discharge, watery eyes, eye pain, foreign body sensation, itching, stinging, and blurred vision. [14] [4] Long term use of ciclosporin at high doses is associated with an increased risk of cancer. [48] [49] Cheaper generic alternatives are available in some countries. [50]
Eye drops or eyedrops are liquid drops applied directly to the surface of the eye usually in small amounts such as a single drop or a few drops. Eye drops usually contain saline to match the salinity of the eye. Drops containing only saline and sometimes a lubricant are often used as artificial tears to treat dry eyes or simple eye irritation ...
Oxymetazoline, sold under the brand name Afrin among others, is a topical decongestant and vasoconstrictor medication. It is available over-the-counter as a nasal spray to treat nasal congestion and nosebleeds, as eye drops to treat eye redness due to minor irritation, and (in the United States) as a prescription topical cream to treat persistent facial redness due to rosacea in adults.
Xylometazoline works by stimulating adrenergic receptors on the lamina propria of blood vessels in the nose. The decongestant effect is due to constriction of large veins in the nose which swell up during the inflammation of any infection or allergy of the nose.
Visine (/ ˌ v aɪ ˈ z iː n /), also known as Vispring, is a brand of eye drops produced by Kenvue. [1] Visine was first introduced in 1958 and was acquired by Pfizer in 1999. [2] [3] In 2006, Johnson & Johnson acquired Visine, along with Pfizer's entire consumer healthcare portfolio. [4]